Chronic myeloid leukaemia trials in France

In France 29 Also abroad 171

29 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Where
Marseille, Paris, Poitiers, Strasbourg
Age
1 year to 18 years
People
50 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07354074
Phase 4Taking people
Asciminib Roll-over Study
Where
Bordeaux, Caen Cedex 9, Clermont-Ferrand, Lille, Lyon, Marseille, Nantes Cedex 1, Nice, Paris, Poitiers, Strasbourg Cedex 2, Toulouse, Vandoeuvre Les Nancy
Age
7 years to 100 years
People
347 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00
Phase 1Taking people
A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Where
Marseille, Pierre-Bénite, Toulouse, Tours
People
225 worldwide
Run by
Janssen Cilag International
See details and how to join2026-525234-39-00 · EU 2026-525234-39-00
Phase 1Enrolling by invitation
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Where
Lille, Marseille, Nantes, Paris, Toulouse, Villejuif
Age
18 years and over
People
120 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06788509 · EU 2024-515457-21-00
Phase 1/2Taking people
A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)
Where
Bordeaux, Lyon, Marseille, Nantes, Paris, Pierre-Bénite
Age
18 years to 64 years
People
330 worldwide
Run by
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
See details and how to joinNCT06163430 · EU 2023-507677-18-00
No phaseTaking people
Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia
Where
Saint-Etienne
Age
18 years and over
People
100
Run by
Centre Hospitalier Universitaire de Saint Etienne
See details and how to joinNCT05130138
Phase 1/2Taking people
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Where
Paris, Poitiers, Rennes
Age
1 year to 17 years
People
70 worldwide
Run by
Incyte Biosciences International Sàrl
See details and how to joinNCT03934372 · EU 2023-509699-41-00
Phase 2/3Taking people
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Where
Nice, Paris, Toulouse Cedex 9
Age
18 years and over
People
316 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT04256317 · EU 2024-515098-93-00
Phase 4Taking people
Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease.
Where
ANGERS Cedex 09, Grenoble Cedex 09, Nantes, Pessac, Rennes Cedex 9, Toulouse Cedex 9
Age
18 years and over
People
365 worldwide
Run by
Medizinische Hochschule Hannover
See details and how to join2024-512503-39-00 · EU 2024-512503-39-00
No phaseNot yet taking people in France
Phenotypic and Functional Characterization of Bone Marrow Macrophages in Chronic Myelomonocytic Leukemia
Where
Nice
Age
55 years and over
People
120
Run by
Centre Hospitalier Universitaire de Nice
See details and how to joinNCT07852494
Phase 2Taking people
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Where
Paris, Poitiers, Toulouse
Age
18 years and over
People
140 worldwide
Run by
Cogent Biosciences, Inc.
See details and how to joinNCT04996875 · EU 2024-511407-42-00
Phase 3Taking people
Study of Olverembatinib (HQP1351) in Patients With CML-CP
Where
Amiens Cedex 1, Bobigny, Nice, Rouen Cedex, Toulouse Cedex 9
Age
18 years and over
People
333 worldwide
Run by
Ascentage Pharma Group Inc.
See details and how to joinNCT06423911 · EU 2024-511495-32-00
No phaseTaking people
Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive Chemotherapy
Where
Nantes
Age
18 years to 99 years
People
60
Run by
Nantes University Hospital
See details and how to joinNCT06439199
Phase 2Taking people
Study to evaluate the safety and efficacy of asciminib in pediatric participants with chronic myeloid leukemia.
Where
Lille Cedex, Marseille, Paris, Poitiers, Strasbourg Cedex 2
Age
Up to 17 years
People
16 worldwide
Run by
Novartis Pharma AG
See details and how to join2025-522138-29-00 · EU 2025-522138-29-00
No phaseNot yet taking people in France
Feasibility Study to Evaluate a Digital Tool for Monitoring Patients Who Have Discontinued Treatment for Chronic Myeloid Leukemia
Where
Le Chesnay
Age
18 years and over
People
20
Run by
Versailles Hospital
See details and how to joinNCT07760311
Phase 2Enrolling by invitation
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
Where
Mulhouse
Age
18 years and over
People
332 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT04093570 · EU 2024-516293-29-01
Phase 1/2Not yet taking people in France
A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies
Where
Marseille, Nice, Paris, Pessac Cedex, Villejuif
Age
18 years and over
People
64 worldwide
Run by
Servier
See details and how to joinNCT07719348 · EU 2025-525128-88-00
Phase 2Taking people
Second STOP After Pioglitazone Priming in CML Patients
Where
Le Chesnay, Le Kremlin-Bicêtre, Lyon, Nantes, Rennes, Toulouse
Age
18 years and over
People
26
Run by
Versailles Hospital
See details and how to joinNCT02889003
No phaseTaking people
Relevance of Peripheral Cells in the Pathophysiology of Chronic Myelomonocytic Leukemia (CMML)
Where
Nice
Age
18 years and over
People
50
Run by
Centre Hospitalier Universitaire de Nice
See details and how to joinNCT03280888
No phaseTaking people
Cohort of Patients With Chronic Myelomonocytic Leukemia
Where
Amiens, Angers, Antony, Bobigny, Corbeil-Essonnes, Grenoble, Le Kremlin-Bicêtre, Lille, Limoges, Nantes, Nice, Nîmes, Paris, Pessac, Poitiers, Rouen, Saint-Brieuc, Toulouse, Tours, Vandœuvre-lès-Nancy, Villejuif
Age
18 years and over
People
5,000
Run by
Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT07512882
Phase 2Taking people
Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.
Where
Bordeaux, Lille, Lyon, Nantes, Paris, Vandœuvre-lès-Nancy
Age
18 years to 99 years
People
20
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06514534 · EU 2024-516049-38-00
Phase 1Taking people
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
Where
Amiens Cedex 1, Bordeaux, Lille Cedex, Limoges, Lyon
Age
18 years and over
People
250 worldwide
Run by
Enliven Therapeutics
See details and how to joinNCT05304377 · EU 2023-503335-18-00
No phaseNot yet taking people in France
Clonal Hematopoiesis of Immunological Significance
Where
Paris
Age
18 years and over
People
5,000
Run by
Assistance Publique - Hôpitaux de Paris
See details and how to joinNCT05969821
No phaseTaking people
Evaluation of Advanced Practice Nurse's Management of Patients With Chronic Myeloid Leukemia
Where
Avignon
Age
18 years and over
People
60
Run by
Centre Hospitalier Henri Duffaut - Avignon
See details and how to joinNCT06082804
Phase 3Not yet taking people in France
A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction
Where
Amiens Cedex 1, Bayonne, Bobigny, Le Chesnay Rocquencourt, Mulhouse, Paris, Perpignan Cedex, Toulouse, Vandoeuvre Les Nancy Cedex, Villejuif
Age
70 years and over
People
262 worldwide
Run by
Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT07082452 · EU 2025-521634-29-00